Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

rch and development 8,161 4,470 20,390 17,640

General and administrative 1,351 680 4,209 1,986

Total operating expenses 9,512 5,150 24,599 19,626

Loss from operations (7,049) (2,687) (17,211) (12,238)

Other income (expense)

Interest income 504 259 1,699 732

Interest expense (193) (279) (647) (735)

Other income (expense), net (36) - 946 2

Total other income (expense) 275 (20) 1,998 (1)

Net loss (6,774) (2,707) (15,213) (12,239)

Dividends and accretion

to redemption value of

redeemable convertible

preferred stock - (1,237) - (3,534)

Net loss attributable

to common stockholders $(6,774) $(3,944) $(15,213) $(15,773)

Basic and diluted net

loss per share

attributable to common

stockholders* $(0.43) $(7.18) $(0.97) $(29.19)

Weighted average shares

used in the computation

of basic and diluted net

loss per share

attributable to

common stockholders *15,733,970 549,481 15,711,212 540,395

* Basic and diluted net loss per share attributable to common

stockholders and weighted average shares outstanding were impacted by

the conversion of preferred stock and issuance of common stock in

connection with the Axonyx merger.


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014 SRI International has ... the National Institute of Allergy and Infectious Diseases (NIAID), ... preclinical development of potential therapies for HIV infection and ... treat HIV and AIDS and the complications and opportunistic ... for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 Three ... be semi-finalists in Livestrong’s Big C Competition. Out of ... are each headed to the semi-final round. In this ... exclusive three-month accelerator program, complete with mentoring from thought-leaders ... , As part of the angelMD commitment to the ...
(Date:7/24/2014)... Mich. , July 24, 2014  Neogen Corporation ... that future forecasts of its potential revenue from new ... call to investors and analysts on July 22, 2014, ... by analysts regarding this research. "It was ... questions about the potential of a new type of ...
(Date:7/24/2014)... 1000 balances – 4 steps – One ... needs and expertly narrows down the mass of product ... even terminals. , First, select the working environment, ... readability instead) and define the accuracy – it’s really ... down the list to models that fit best with ...
Breaking Biology Technology:National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2Neogen comments on SenesTech 2
... 28 Beckman Coulter, Inc. (NYSE: ... Directors declared a quarterly dividend payout of seventeen ... payable on May 22, 2009 to all stockholders ... payout represents the 80th consecutive, quarterly payout of ...
... ANGELES, April 28 MMR Information Systems (OTC ... subsidiary, MyMedicalRecords, Inc. (collectively, "MMR") provides Web-based consumer-controlled ... ) and electronic safe deposit box storage solutions ... free Personal Health Record and free surgical masks ...
... its financial results for the first quarter of fiscal 2009 ... will be hosted by management at 11 a.m. ET following ... on the company,s Web site, www.usoncology.com , ... announcement. US/Canada Dial-in #: (877) 615-1716 , Conference ...
Cached Biology Technology:MMR Offers Free Surgical Masks to Call Attention to Importance of Personal Health Records in Preparing for Possible Swine Flu Pandemic 2MMR Offers Free Surgical Masks to Call Attention to Importance of Personal Health Records in Preparing for Possible Swine Flu Pandemic 3MMR Offers Free Surgical Masks to Call Attention to Importance of Personal Health Records in Preparing for Possible Swine Flu Pandemic 4US Oncology to Report 2009 First Quarter Operating Results 2
(Date:7/24/2014)... current biodiversity, the product of 3.5 billion years of ... history of life. But it may be reaching a ... literature and analysis of data published in Science ... loss and decline of animals is contributing to what ... sixth mass biological extinction event. , Since 1500, more ...
(Date:7/24/2014)... Einstein College of Medicine of Yeshiva University have ... for Parkinson,s Research to translate a basic science finding ... project will test chemical compounds on a newly identified ... acts on an underlying cause of the disease. ... manage their symptoms, we are eager to stop or ...
(Date:7/24/2014)... and one of the most species richness biome of ... current levels of diversity might be still underestimated. In ... the description of new endemic species of this biome ... of samples for DNA analysis. , Using a ... analysis, researchers from the University of Richmond ...
Breaking Biology News(10 mins):Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3A tiny new species of frog from Brazil with a heroic name 2
... The Federation of American Societies for Experimental Biology ... Research Conference (SRC): Mobile DNA in Mammalian Genomes. ... forces shaping the structure and altering functions within mammalian ... conference will explore the explosion of data from high ...
... Societies for Experimental Biology (FASEB) announces the opening ... Gastrointestinal Tract XV: Epithelia, Microbes, Inflammation and Cancer. ... and Reversible Acetylation in Signaling and Disease is ... biological functions of reversible protein acetylation are explored ...
... University chemistry professor has begun imbedding magnetic nanoparticles ... more than 40,000 Americans must replace their knee ... Samia, an assistant professor who specializes in metallic ... Science Foundation-CAREER grant to create new materials and ...
Cached Biology News:New effort to find why replacement hips and knees go bad 2
Standard 2" and 3" Fiberboard Boxes can be sold separately or with 16, 25, 36, 49, 64, 81 or 100 cell dividers. Fiberboard boxes can also be ordered with corresponding freezer racks...
Whole blood is collected from mice (Swiss Webster, 8-10 weeks old,either sex) and processed within 45 minutes of collection. The complement is then filtered and pooled on ice, bottled and stored at -...
... Anti-HMGN2/HMG-17 Immunogen : Recombinant ... pH7.4, 5mg/ml BSA, 0.15M NaCl, ... addition of glycerol to 30% ... immunoblot on acid extracts of ...
... Assay, 96 wells. ELISA.Specific for total MMP-3: ... No cross-reactivity with MMP-1, -2, -9. Range: ... with cell culture supernatant, serum, plasma and ... -30 C. Category: Drug Screening & ...
Biology Products: